Outcomes4Me is a 2024 Fast Company World Changing Idea! Learn more >>
Suzanne Garner
Cancer Survivor, Outcomes4Me User
We’re the only non-metastatic stage 3 HER2- breast cancer app that integrates with the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), from the not-for-profit alliance of 33 leading cancer centers. The NCCN Guidelines® include comprehensive guidance related to all FDA-approved treatment options.
We gather non-metastatic stage 3 HER2- breast cancer treatment recommendations typically meant for oncologists and use Artificial Intelligence (AI) to translate that information so you can understand it, putting you in control. With this knowledge, you can feel empowered to make the best medical decisions with your care team.
With our free non-metastatic stage 3 HER2- breast cancer app, you’ll get:
Gain direct access to personalized treatment options so you can have more informed conversations with your care team.
Rely on us to help your patients get access to the best non-metastatic stage 3 HER2- breast cancer care and resources, and save time in your day. We’re here to help and won’t ever get in the way.
Accelerate patient access to your treatments and expand the reach of your non-metastatic stage 3 HER2- breast cancer research and clinical trials.
Get all the information you need to take a more active role in treating your non-metastatic stage 3 HER2- breast cancer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
We use cookies and other tracking technologies to offer you a better experience, personalize content and ads, enable social media functionality and to analyze our performance and site traffic. By clicking ‘Accept’ or closing this banner, you understand your information may be disclosed to our third-party partners. For more information, visit our Privacy Policy.
By clicking the “Subscribe Now” button you’re agreeing to our Terms of Service and Privacy Policy.